Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MONTES ARCHIMEDES ACQUISITION CORP.

(MAAC)
  Report
SummaryQuotesChartsNewsCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Biotech firm Roivant Sciences to go public via $7.3 bln SPAC deal

05/03/2021 | 07:24am EDT

May 3 (Reuters) - Roivant Sciences has agreed to go public through a merger with a blank-check firm backed by former KKR & Co Inc dealmaker Jim Momtazee, in a deal that values the Swiss biotech company at $7.3 billion.

The deal with Montes Archimedes Acquisition Corp, a special purpose acquisition company (SPAC), is expected to deliver up to $611 million of gross proceeds to fund discovery and development programs, the companies said on Monday.

That includes up to $411 million currently held in the SPAC's trust account and $200 million from new and existing investors including Fidelity Management and SoftBank Group Corp unit SB Management.

Shares of Montes Archimedes Acquisition were up 3.5% at $10.2 before the bell.

Montes Archimedes went public in a $400 million initial public offering (IPO) in October last year and is sponsored by Patient Square Capital Patient, which was launched by Momtazee to pursue private equity deals in the healthcare sector.

SPACs are shell companies that raise funds through an IPO to take a private company public through a merger at a later date.

Founded in 2014, Roivant has multiple subsidiaries focused on developing treatments for multiple cancers, nervous system and immune system disorders, including Immovovant Inc and Sio Gene Therapies Inc.

In February, the company said it would buy drug developer Silicon Therapeutics for $450 million to strengthen its artificial intelligence capabilities for drug discovery.

Following its acquisition, Roivant will continue to be led by Chief Executive Officer Matthew Gline, while founder Vivek Ramaswamy will remain executive chairman.

The biotech firm said it expects the deal to close in the third quarter of this year, after which it plans to list on the Nasdaq under the ticker symbol "ROIV". (Reporting by Niket Nishant and Dania Nadeem in Bengaluru; Editing by Ramakrishnan M.)


© Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
MONTES ARCHIMEDES ACQUISITION CORP. -0.20% 9.86 Delayed Quote.-3.05%
SIO GENE THERAPIES, INC. 3.38% 2.14 End-of-day quote.-23.02%
SOFTBANK GROUP CORP. 0.72% 8528 End-of-day quote.5.83%
All news about MONTES ARCHIMEDES ACQUISITION CORP.
05/14MONTES ARCHIMEDES ACQUISITION  : 10-K/A - Management's Discussion and Analysis o..
AQ
05/14MONTES ARCHIMEDES ACQUISITION CORP  : Non-Reliance on Previous Financials, Audit..
AQ
05/03MONTES ARCHIMEDES ACQUISITION  : Biopharmaceutical Firm Roivant Sciences to Go P..
MT
05/03Biotech firm Roivant Sciences to go public via $7.3 bln SPAC deal
RE
05/03MONTES ARCHIMEDES ACQUISITION  : Biotech Roivant to go public via $7.3 bln SPAC ..
RE
05/03MONTES ARCHIMEDES ACQUISITION CORP  : Entry into a Material Definitive Agreement..
AQ
05/03MONTES ARCHIMEDES ACQUISITION  : Roivant Sciences and Montes Archimedes Acquisit..
PR
03/22MONTES ARCHIMEDES ACQUISITION  : Management's Discussion and Analysis of Financi..
AQ
More news
Financials (USD)
Sales 2020 - - -
Net income 2020 -0,77 M - -
Net cash 2020 1,70 M - -
P/E ratio 2020 -
Yield 2020 -
Capitalization 506 M 506 M -
EV / Sales 2019
EV / Sales 2020 -
Nbr of Employees -
Free-Float 80,0%
Chart MONTES ARCHIMEDES ACQUISITION CORP.
Duration : Period :
Montes Archimedes Acquisition Corp. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MONTES ARCHIMEDES ACQUISITION CORP.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Managers and Directors
NameTitle
James C. Momtazee Chairman, President & Chief Executive Officer
Maria Walker Chief Financial Officer
George S. Barrett Independent Director
Stephen Newman Oesterle Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MONTES ARCHIMEDES ACQUISITION CORP.-3.05%506
INVESTOR AB (PUBL)22.11%66 983
CK HUTCHISON HOLDINGS LIMITED15.16%30 932
AB INDUSTRIVÄRDEN (PUBL)19.26%16 665
HAL TRUST30.60%15 822
KINNEVIK AB-1.10%14 008